Shares of Humanigen, Inc. (NASDAQ:HGEN – Get Rating) have been assigned a consensus rating of "Hold" from the seven ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $19.50.

A number of analysts recently weighed in on the company. Cantor Fitzgerald downgraded Humanigen from an "overweight" rating to a "neutral" rating in a report on Wednesday, July 13th. Credit Suisse Group downgraded Humanigen from a "neutral" rating to an "underperform" rating in a report on Wednesday, July 13th. HC Wainwright downgraded Humanigen from a "buy" rating to a "neutral" rating in a report on Wednesday, July 13th. Finally, Roth Capital downgraded Humanigen from a "buy" rating to a "neutral" rating in a report on Wednesday, July 13th.

Insiders Place Their Bets

In related news, insider Dale Chappell acquired 545,488 shares of the business's stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $2.23 per share, with a total value of $1,216,438.24. Following the transaction, the insider now directly owns 8,675,081 shares of the company's stock, valued at $19,345,430.63. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 21.70% of the company's stock.

Hedge Funds Weigh In On Humanigen

Humanigen Stock Performance

Shares of NASDAQ:HGEN opened at $0.49 on Wednesday. The company has a fifty day moving average of $2.09 and a 200-day moving average of $2.43. The company has a market capitalization of $34.68 million, a PE ratio of -0.15 and a beta of -0.79. Humanigen has a 52-week low of $0.47 and a 52-week high of $18.65.

Humanigen (NASDAQ:HGEN – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.17. The company had revenue of $1.04 million during the quarter, compared to the consensus estimate of $1.04 million. Humanigen had a negative net margin of 4,640.77% and a negative return on equity of 4,882.88%. On average, equities analysts forecast that Humanigen will post -0.91 EPS for the current fiscal year.

Humanigen Company Profile

(Get Rating)

Humanigen, Inc, a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.

Further Reading

• Get a free copy of the StockNews.com research report on Humanigen (HGEN)
• Financial services firm Block stock has fallen (-59%) in 2022
• Hold Pfizer Today With Catalysts for Further Growth Tomorrow
• NVIDIA Stock is a Winding Up for a Record Setting Second Half
• Johnson & Johnson Continues to Prove its Value in a Volatile Year
• MarketBeat: Week in Review 7/11 – 7/15

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.